Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 2:56 PM ET

Pharmaceuticals

Company Overview of Acetylon Pharmaceuticals, Inc.

Company Overview

Acetylon Pharmaceuticals, Inc. discovers and develops selective small molecule histone deacetylase inhibitors and other targeted drugs for the treatment of cancers, inflammatory, neurodegenerative, genetic, and infectious diseases. It has a strategic partnership with Celgene Corporation. The company was founded in 2008 and is based in Boston, Massachusetts.

70 Fargo Street

Suite 205

Boston, MA 02210

United States

Founded in 2008

Phone:

617-245-1300

Fax:

617-245-1301

Key Executives for Acetylon Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 58
Co-Founder and Chairman of the Board
Age: 52
Scientific Founder, Director and Member of the Advisory Board
Age: 42
Scientific Founder and Member of the Advisory Board
Scientific Founder, Director and Member of the Advisory Board
Age: 64
Compensation as of Fiscal Year 2015.

Acetylon Pharmaceuticals, Inc. Key Developments

Acetylon Pharmaceuticals, Inc. Presents Positive Preliminary Data from its Phase 1B/2 Trial of Ricolinostat in Combination with Pomalyst

Acetylon Pharmaceuticals, Inc. announced that the company presented positive preliminary data from its Phase 1b/2 trial of ricolinostat in combination with Pomalyst® (pomalidomide) and dexamethasone in patients with relapsed-and-refractory multiple myeloma at the 20thCongress of the European Hematology Association, which took place June 11-14, 2015, in Vienna, Austria. Initial data from the evaluation of 28 of the planned 66 patients in the Phase 2 portion of the study reported an overall response rate of 29% at an early median follow-up of 12 weeks, which compares favorably to the historical control of 16.6% at 18.1 weeks with Pomalyst and dexamethasone alone in a similar patient population. Clinical benefit, defined as minimal response or greater, was 50%, and 68% of patients achieved stable disease or better. In the overall study (Phase 1 and Phase 2, n=39), ricolinostat was well-tolerated in combination with Pomalyst. The most common treatment-emergent adverse events were fatigue (41%), diarrhea (38%), and neutropenia (36%), the majority of which were low grade. Grade 3 and 4 adverse events, apart from neutropenia (26%), were uncommon (=8%). Ricolinostat is an oral selective HDAC6 inhibitor in multiple clinical studies for the potential treatment of multiple myeloma and lymphoma.

Acetylon Pharmaceuticals, Inc. Presents at Boston CEO Conference, May-26-2015 11:30 AM

Acetylon Pharmaceuticals, Inc. Presents at Boston CEO Conference, May-26-2015 11:30 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Walter C. Ogier, Chief Executive Officer, President and Director.

Acetylon Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM

Acetylon Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Walter C. Ogier, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Clinical Trials Services, Inc. United States
Carman Research United States
Aventura Laboratories, Inc. United States
Montigen Pharmaceuticals Inc. United States
Pharmanex, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Acetylon Pharmaceuticals, Inc., please visit www.acetylon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.